Rationale in Usage of Immunomodulators for Management of Head, Face and Neck Cancers
Sonal Vahanwala, Sandeep S Pagare, Runuk Singhi, Chaitanya D Nayak
Citation Information :
Vahanwala S, Pagare SS, Singhi R, Nayak CD. Rationale in Usage of Immunomodulators for Management of Head, Face and Neck Cancers. Int J Head Neck Surg 2012; 3 (3):154-157.
Pagare SS, Singhi R, Vahanwala S Nayak CD. Rationale in Usage of Immunomodulators for Management of Head, Face and Neck Cancers. Int J Head and Neck Surg 2012;3(3):154-157.
New and established corticosteroids in dermatology. Am J Clin Dermatol 2002;3:47.
Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatology 1967;48:181.
Hypertrichosis in patients receiving cyclosporine therapy. Clin Exp Dermatol 1987;12(3):191-96.
Effect of topical cyclosporine rinse on oral lichen planus: A double-blind analysis. N Engl J Med 1990;323:290-94.
Combination immunosuppressant and topical steroid therapy for treatment of recurrent major aphthae: A case report Oral Surg, Oral Med, Oral Pathol 1990 Jan;69(1):42-44.
Guidelines for the management of pemphigus vulgaris. Brit J Dermatol 2003;149: 926-37.
Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy Ann Int Med 1993 Sep 1;119(5): 366-69.
Pharmacology and Pharmacotherauptics (22nd ed), Mumbai, India. Popular Prakashan 2011:819.
Management of thalidomide toxicity. J Support Oncology 2003Sep-Oct;1(3):194-205.
Fitzpatrick's Dermatology in General Medicine (7th ed), New York. McGraw Hill Publications 2007;1:2217.
